|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results show that HT in patients with PTC is associated with a low probability of BRAF (V600E) mutations.
|
25312294 |
2015 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Further, type I collagen enhanced the motility of Braf(V600E)/Pten(-/-)/TPO-Cre tumor cells in vitro In clinical specimens, we found COL1A1 and LOX to be upregulated in PTC and expressed at highest levels in PDTC and anaplastic thyroid cancer.
|
26818109 |
2016 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
All patients had confirmation of papillary thyroid cancer after histology, with no differences being seen in pTNM presentation between patients with BRAF wild-type and patients with BRAF V600E mutation.
|
23925579 |
2014 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Vemurafenib showed antitumour activity in patients with progressive, BRAF(V600E)-positive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a multikinase inhibitor.
|
27460442 |
2016 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A valuable adjunct to FNA diagnosis of papillary thyroid carcinoma: in-house PCR assay for BRAF T1799A (V600E).
|
20607744 |
2011 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We compared the clinicopathologic parameters and BRAF V600E mutation status of 121 elderly (age ≥65 years) PTC patients who underwent thyroidectomy from January 2007 to December 2009 to a consecutive cohort of 98 younger (age <65 years) PTC patients.
|
21594703 |
2011 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dabrafenib can stimulate radioiodine uptake in patients with metastatic BRAF V600E-mutant iodine-refractory PTC, representing a potential new therapeutic approach for these patients.
|
25549723 |
2015 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The frequency of BRAF(V600E) mutation was similar in patients with PMC and PTC (65.6% vs 67.2%).
|
19475551 |
2010 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266 (4.1%) and RET/PTC in 55/266 (20.7%; 42/266 (15.8%) RET/PTC1 and 13/266 (4.9%) RET/PTC3).
|
21498916 |
2011 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this article, we review the pathogenesis of PTC, and the clinical implications of BRAF(V600E) mutation in the diagnosis, prognosis and potential targeted therapeutic strategies for thyroid cancers.
|
20230995 |
2010 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Seven of the 9 indeterminate and suspicious cases with the BRAF V600E mutation had surgical follow-up, and they were all confirmed to be PTC.
|
30620446 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We were unable to identify peripheral BRAF(V600E) mutations in patients with papillary thyroid cancer using real-time PCR.
|
23161556 |
2013 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Association of BRAF V600E Mutation With Tissue Inhibitor of Metalloproteinase-3 Expression and Clinicopathological Features in Papillary Thyroid Cancer.
|
29868127 |
2018 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These resu</span>lts suggest that BRAF(V599E) mutation is frequent in the etiopathogenesis of PTC.
|
12881714 |
2003 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We analyzed mutations of BRAF (V600E) and TERT promoter (C228T, C250T) in tumor DNA from 141 patients (75 with classical variant PTC, CVPTC; 66 with follicular variant PTC, FVPTC) recruited through a multi-center study.
|
31454788 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, high Mig-6 expression was independently predictive of greater disease-free survival in BRAF(V600E)-positive PTC.
|
19040996 |
2008 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In human BRAF(V600E) (+) PTCs, ERK phosphorylation is decreased compared to normal thyroid glands and the observed decrease in ERK1/2 MAPK phosphorylation in BRAF(V600E) (+) PTCs may be associated with increased MKP-3 activity.
|
23544999 |
2013 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We confirm that V600E mutation is a frequent and specific event in PTC.
|
21716161 |
2011 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was detected in 17.4% of FVPCs and in 66.6% of PTCs, whereas uncommon BRAF mutations were detected only in FVPCs.
|
26230187 |
2015 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, VE1 antibody can be used on thyroid microhistologic specimens to detect BRAF(V600E)-mutated PTC before surgery.
|
24570209 |
2014 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation analysis is a highly sensitive diagnostic tool in the diagnosis of papillary thyroid carcinomas.
|
25616949 |
2015 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF mutation in exon 15 (V600E) was found in 42/54 (77.8%) recurrent PTC patients.
|
19147753 |
2009 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Significance of allelic percentage of BRAF c.1799T > A (V600E) mutation in papillary thyroid carcinoma.
|
24748129 |
2014 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, B-Raf(V600E) plays an important role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis.
|
20498063 |
2010 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, the expression levels of NIS and TSHR were remarkably lower in PTCs harboring the BRAF V600E mutation.
|
19152441 |
2009 |